Literature DB >> 24806111

Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths.

Vikas Prasad1, Lisa Bodei, Mark Kidd, Irvin M Modlin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24806111     DOI： 10.1007/s00259-014-2780-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  43 in total

Review 1.  Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms.

Authors:  Richard P Baum; Harshad R Kulkarni; Cecilia Carreras
Journal:  Semin Nucl Med       Date:  2012-05       Impact factor: 4.446

2.  Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.

Authors:  Renzo Cescato; Kimberly A Loesch; Beatrice Waser; Helmut R Mäcke; Jean E Rivier; Jean Claude Reubi; Agnes Schonbrunn
Journal:  Mol Endocrinol       Date:  2009-11-12

3.  Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.

Authors:  Hendrik Bergsma; Esther I van Vliet; Jaap J M Teunissen; Boen L R Kam; Wouter W de Herder; Robin P Peeters; Eric P Krenning; Dik J Kwekkeboom
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-12       Impact factor: 3.043

Review 4.  Rationale for the use of somatostatin analogs as antitumor agents.

Authors:  C Susini; L Buscail
Journal:  Ann Oncol       Date:  2006-06-26       Impact factor: 32.976

5.  Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Authors:  Roelf Valkema; Stanislas A Pauwels; Larry K Kvols; Dik J Kwekkeboom; Francois Jamar; Marion de Jong; Raffaella Barone; Stephan Walrand; Peter P M Kooij; Willem H Bakker; Janet Lasher; Eric P Krenning
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

Review 6.  Radioimmunotherapy of lymphoma: Bexxar and Zevalin.

Authors:  Stanley J Goldsmith
Journal:  Semin Nucl Med       Date:  2010-03       Impact factor: 4.446

Review 7.  PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.

Authors:  Edward M Wolin
Journal:  Cancer Lett       Date:  2013-02-16       Impact factor: 8.679

Review 8.  Medical treatment of neuroendocrine tumours.

Authors:  H Christian Weber
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-02       Impact factor: 3.243

9.  Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.

Authors:  Mark Kidd; Ignat Drozdov; Richard Joseph; Roswitha Pfragner; Michael Culler; Irv Modlin
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

10.  Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate.

Authors:  Esther I van Vliet; Eric P Krenning; Jaap J Teunissen; Hendrik Bergsma; Boen L Kam; Dik J Kwekkeboom
Journal:  J Nucl Med       Date:  2013-10       Impact factor: 10.057
View more
  4 in total

1.  The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis.

Authors:  Seong-Jang Kim; Kyoungjune Pak; Phillip J Koo; Jennifer J Kwak; Samuel Chang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-09       Impact factor: 9.236

2.  Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT.

Authors:  Kevin Zwirtz; Juliane Hardt; Güliz Acker; Alexander D J Baur; Marianne Pavel; Kai Huang; Winfried Brenner; Vikas Prasad
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

3.  Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.

Authors:  Josephine Graf; Ulrich-Frank Pape; Henning Jann; Timm Denecke; Ruza Arsenic; Winfried Brenner; Marianne Pavel; Vikas Prasad
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-14       Impact factor: 9.236

4.  Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.

Authors:  Mattias Sandström; Ezgi Ilan; Anna Karlberg; Silvia Johansson; Nanette Freedman; Ulrike Garske-Román
Journal:  EJNMMI Phys       Date:  2015-10-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.